-
3.92025 Impact Factor
-
4.22025 5 Year Impact Factor
-
7.52025 CiteScore
Editor-in-Chief
Professor Claudia Mauri, University College London
New 'Treatment of…’ Series
Through the ‘Clinical & Experimental Treatment of...’ series, we aim to present a thorough exploration of immunopathology, treatment options, and future developments in immune-mediated diseases. If you have relevant insights you’d like to share with the community, this series provides an excellent platform!
Read the articles and get involved
Review for the BSI Journals
Peer review is essential for the validation, enhancement, and assessment of research published in the British Society for Immunology journals. We welcome colleagues at any stage of their career to become peer reviewers.
Learn more and sign up
Review Series
Access topical research in freely available Review Series published in Clinical & Experimental Immunology, collated expert special guest editors.
Browse Review Series
Virtual Issues
Rediscover Virtual Issues published in Clinical & Experimental Immunology and explore the full archive of free article collections today.
Access Virtual Issues
Submit your research
Publish with us. Read our instructions to authors for details on peer review, article types and the submission process.
Find out more
Author resources
Learn about how to submit your article, our publishing process and tips on how to promote your article.
Find out more
Email alerts
Register to receive table of contents and advance access alerts as soon as new issues of Clinical & Experimental Immunology are published online.
Register now
About the BSI
Clinical & Experimental Immunology is an official journal of the British Society for Immunology (BSI). The BSI is the leading UK membership organization working with scientists and clinicians from academia and industry to forward immunology application around the world.
Learn more
Meet the Editorial Board
Clinical & Experimental Immunology is edited by leading immunologist Professor Claudia Mauri, supported by a global Editorial Board of experts from academia and industry.
Meet the Editorial Board
The molecular links between genetic susceptibility and immune dysregulation in eczema remain incompletely understood. By integrating genome-wide association data with transcriptomic and brain proteomic resources, we prioritised TRAF3, an immune-signalling adaptor, with convergent support from peripheral transcriptomic, brain proteomic and blood-based genetic analyses. These findings highlight TRAF3-related regulation as a priority for functional investigation and generate hypotheses about the relevance of brain-associated molecular signals to eczema susceptibility.
IgA nephropathy (IgAN) is considered a tonsillar focal disease, although the mechanisms linking tonsillar immune responses to renal injury remain unclear. We found increased accumulation of CXCR3-positive T cells in IgAN tonsils, enhanced chemotactic responses to IP-10, and increased Gd-IgA1 production by tonsillar B cells in the presence of CXCR3-positive T cells; moreover, CXCR3-positive T cells were detected in renal lesions, and their tonsillar abundance was associated with clinical remission after tonsillectomy. These findings suggest that tonsillar CXCR3-positive T cells contribute to IgAN pathogenesis by promoting Gd-IgA1 production and potentially migrating to renal lesions via the CXCR3–IP-10 axis, supporting the tonsils as a disease focus and a therapeutic target.
ICOS-high circulating follicular helper T (cTfh) cells are expanded in myasthenia gravis (MG) and associated with disease severity, but the factors driving this skewing remain unclear. We found that miR-146a and miR-155 were elevated in peripheral blood mononuclear cells from anti-acetylcholine receptor antibody-positive MG patients, and that miR-155, but not miR-146a, correlated with the frequency of ICOS-high cTfh cells and decreased after immunotherapy. Single-cell RNA sequencing further showed that MIR155HG was most highly expressed in a Tfh-like CD4+ T-cell cluster expanded in MG, implicating miR-155 in the pathogenic activation of circulating Tfh cells.
Myasthenia gravis (MG)-associated myocarditis is a rare but life-threatening complication whose immune basis remains poorly defined. Integrating single-cell RNA sequencing with paired T cell receptor (TCR) repertoire profiling of peripheral blood, we show that MG-myocarditis is driven not by shifts in immune cell abundance but by a pronounced transcriptional reconfiguration–pro-inflammatory skewing of classical CD14+ monocytes alongside enhanced antigen-presenting signatures in CD16+ monocytes and conventional dendritic cells (cDCs). Expanded TCR clonotypes in CD8+ effector memory (EOMES+) and effector subsets show preferential predicted reactivity to cardiac antigens including Titin, MYO10 and MYH6, supporting a hypothetical model in which cDC- and monocyte-mediated presentation of cardiac antigens primes pathogenic CD8+ T cells to drive myocardial injury.
